Author

James O. Lindsay

Exploring the evolution of care in Crohn’s disease (Janssen)
Exploring the evolution of care in Crohn’s disease (Janssen)

James O. Lindsay  et al.

Preventive and screening measures
Preventive and screening measures

James O. Lindsay

A RANDOMISED CONTROLLED CLINICAL TRIAL OF AUTOLOGOUS STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH TREATMENT REFRACTORY CROHN’S DISEASE (LOW INTENSITY THERAPY EVALUATION): ASTICLITE
A RANDOMISED CONTROLLED CLINICAL TRIAL OF AUTOLOGOUS STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH TREATMENT REFRACTORY CROHN’S DISEASE (LOW INTENSITY THERAPY EVALUATION): ASTICLITE

James O. Lindsay  et al.

A RANDOMISED CONTROLLED CLINICAL TRIAL OF AUTOLOGOUS STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH TREATMENT REFRACTORY CROHN’S DISEASE (LOW INTENSITY THERAPY EVALUATION): ASTICLITE
A RANDOMISED CONTROLLED CLINICAL TRIAL OF AUTOLOGOUS STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH TREATMENT REFRACTORY CROHN’S DISEASE (LOW INTENSITY THERAPY EVALUATION): ASTICLITE

Targeting IL-23: emerging possibilities in the management of Crohn’s disease (AbbVie) - Inhibition of IL-23: a pathway worth exploring
Targeting IL-23: emerging possibilities in the management of Crohn’s disease (AbbVie) - Inhibition of IL-23: a pathway worth exploring

James O. Lindsay

Webinar: COVID-19 & Digestive Health #1 | IBD & Endoscopy
Webinar: COVID-19 & Digestive Health #1 | IBD & Endoscopy

James O. Lindsay  et al.

Therapeutic Strategies in Crohn’s Disease: Does Pathophysiology Matter? (Takeda Pharmaceuticals International AG)
Therapeutic Strategies in Crohn’s Disease: Does Pathophysiology Matter? (Takeda Pharmaceuticals International AG)

James O. Lindsay  et al.

A MATCHING-ADJUSTED INDIRECT COMPARISON OF MAINTENANCE ORAL FILGOTINIB VERSUS INTRAVENOUS VEDOLIZUMAB FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
A MATCHING-ADJUSTED INDIRECT COMPARISON OF MAINTENANCE ORAL FILGOTINIB VERSUS INTRAVENOUS VEDOLIZUMAB FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Stool tests in nutrition-adjust the test to the disease-and patient
Stool tests in nutrition-adjust the test to the disease-and patient

James O. Lindsay

UPADACITINIB TREATMENT IMPROVES HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 INDUCTION STUDIES U-ACHIEVE AND U-ACCOMPLISH
UPADACITINIB TREATMENT IMPROVES HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 INDUCTION STUDIES U-ACHIEVE AND U-ACCOMPLISH

James O. Lindsay  et al.

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

James O. Lindsay  et al.

A MATCHING-ADJUSTED INDIRECT COMPARISON OF MAINTENANCE ORAL FILGOTINIB VERSUS INTRAVENOUS VEDOLIZUMAB FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
A MATCHING-ADJUSTED INDIRECT COMPARISON OF MAINTENANCE ORAL FILGOTINIB VERSUS INTRAVENOUS VEDOLIZUMAB FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

James O. Lindsay  et al.

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY
EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY

James O. Lindsay  et al.

IMPACT OF CONCOMITANT THIOPURINE ON THE EFFICACY AND SAFETY OF FILGOTINIB TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY
IMPACT OF CONCOMITANT THIOPURINE ON THE EFFICACY AND SAFETY OF FILGOTINIB TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

James O. Lindsay  et al.

European Crohn’s and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease
European Crohn’s and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease

James O. Lindsay  et al.

UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care
UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care

James O. Lindsay  et al.

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY
EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY

James O. Lindsay  et al.

Item 1 - 17 / 17
1